title: Increased whole blood viscosity during coronary artery bypass surgery. Studies to evaluate the effects of soluble fibrin and poloxamer 188.
abstract: This study was designed to test the hypothesis that soluble fibrin complexes resulting from the trauma of surgery could produce elevated blood viscosity, to characterize the soluble fibrin polymers, and to evaluate in vitro the effect of a new hemorheologic agent, poloxamer 188, on viscosity in these abnormal situations. Ten patients undergoing aortocoronary bypass surgery were studied before and at various times after surgery. By 6 h after surgery, the mean hematocrit decreased by 23%, fibrinogen decreased 48%, and erythrocyte sedimentation rate decreased 33%, whole blood viscosity at a low shear rate rose on average of 69% and soluble fibrin rose 118%. Over the 6-day observation period, the concentrations of soluble fibrin paralleled the changes in viscosity, whereas the concentrations of fibrinogen varied nearly inversely with viscosity. The effects of various forms of fibrinogen and fibrin were tested by additions to normal blood. Soluble fibrin polymers, but not fibrin monomers, increased blood viscosity two to three fold. Poloxamer 188 reduced the viscosity of all patient samples to the normal range. These data support the hypothesis that increased whole blood viscosity at low shear rates is caused by hydrophobic adhesion of fibrin polymers to red cells and that poloxamer 188 normalizes viscosity by effectively disrupting the weak hydrophobic bonds.
authors.affiliation: Department of Pathology, Emory University, Atlanta, Georgia 30322.
authors.forename: R L
authors.initials: RL
authors.lastname: Hunter
authors.forename: C
authors.initials: C
authors.lastname: Papadea
authors.forename: C J
authors.initials: CJ
authors.lastname: Gallagher
authors.forename: D C
authors.initials: DC
authors.lastname: Finlayson
authors.forename: I J
authors.initials: IJ
authors.lastname: Check
mesh_terms: D001704:Biopolymers; D001799:Blood Sedimentation / Q000187:drug effects; D001809:Blood Viscosity / Q000187:drug effects*; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D005337:Fibrin / Q000378:metabolism / Q000502:physiology*; D005340:Fibrinogen / Q000378:metabolism; D006400:Hematocrit; D006801:Humans; D008970:Molecular Weight; D011060:Poloxalene / Q000494:pharmacology*; D011092:Polyethylene Glycols / Q000494:pharmacology*; D012995:Solubility
chemical_list: D001704:Biopolymers; D011092:Polyethylene Glycols; D005337:Fibrin; D005340:Fibrinogen; D011060:Poloxalene